During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of patient treatment Overall safety profile of BRIUMVI rema ...

17% of patients treated with BRIUMVI continuously for 6 years achieved Confirmed Disability Improvement (CDI) lasting at least 24 weeks compared to 13.3% of patients who switched from teriflunomide to ...

Roche presented new data at ECTRIMS 2025 confirming that OCREVUS provides sustained protection against disability progression and maintains a con ...

In view of persistent fever and cough, and the new onset of an accentuated confluent maculopapular rash, the patient was ...

A four-layer ultralight foam chamois is used, aimed at providing plenty of comfort. It’s fast drying and anti-microbial to ...

Economists have called on the Monetary Policy Committee of the Central Bank of Nigeria to significantly cut interest rates to drive economic growth and provide a conducive environment for businesses ...

Discover Quince Therapeutics’ breakthrough drug-delivery platform aiming to safely treat rare diseases with encapsulated steroids.

When John Pitzel started the 2025 Tokyo Marathon, he knew that it was going to be hot. Tokyo is typically 50 degrees in early March, but on March 2, the temperature hit 68 degrees—perfect weather for ...

Stimulation of the A13 brain region restores motor function in Parkinson's disease mouse models by alleviating bradykinesia and akinesia.